Small molecule · Inhibitor of MET proto-oncogene receptor tyrosine kinase (MET), vascular endothelial growth factor receptor 1 (FLT1) and vascular endothelial growth factor receptor 2 (KDR) · developed by Exelixis
From the indications section of the FDA label (version of Oct 19, 2025). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.